Incyte Corp
INCYFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Incyte Corp Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 10, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Palouse Capital Management, Inc. | 2026-03-31 | 1,223 | $115K | SEC filing |
| 180 WEALTH ADVISORS, LLC | 2026-03-31 | 6,877 | $647K | SEC filing |
| NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC | 2026-03-31 | 5,350 | $504K | SEC filing |
| Lloyd Advisory Services, LLC. | 2026-03-31 | 352 | $33.1K | SEC filing |
| ELEVATION WEALTH PARTNERS, LLC | 2026-03-31 | 3 | $283 | SEC filing |
| VOYA INVESTMENT MANAGEMENT LLC | 2026-03-31 | 106,738 | $10M | SEC filing |
| Catalio Capital Management, LP | 2026-03-31 | 182,101 | $17.1M | SEC filing |
| ASHFORD CAPITAL MANAGEMENT INC | 2026-03-31 | 165,247 | $15.6M | SEC filing |
| HIGHLINE WEALTH PARTNERS LLC | 2026-03-31 | 62 | $5.84K | SEC filing |
| Savant Capital, LLC | 2026-03-31 | 2,395 | $225K | SEC filing |
| Whipplewood Advisors, LLC | 2026-03-31 | 59 | $5.55K | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 33,976 | $3.2M | SEC filing |
| CURIO WEALTH, LLC | 2026-03-31 | 2 | $188 | SEC filing |
| &PARTNERS | 2026-03-31 | 2,729 | $257K | SEC filing |
| Anchor Investment Management, LLC | 2026-03-31 | 500 | $47.1K | SEC filing |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 2026-03-31 | 53,615 | $5.05M | SEC filing |
| DIADEMA PARTNERS LP | 2026-03-31 | 78,029 | $7.34M | SEC filing |
| Jump Financial, LLC | 2026-03-31 | 56,437 | $5.31M | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 31,835 | $3M | SEC filing |
| NOMURA HOLDINGS INC | 2026-03-31 | 14,375 | $1.35M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Incyte Corp's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-19 · CAGNONI PABLO J: Larger than 42 of the 45 other insider sales of Common Stock on file. SEC filing
- 2025-12-16 · Morrissey Michael James: Larger than 44 of the 45 other insider sales of Common Stock on file. SEC filing
- 2025-12-02 · Stein Steven H: Larger than 43 of the 45 other insider sales of Common Stock on file. SEC filing
- 2025-11-10 · Hoppenot Herve: Larger than all 45 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-04 | Tray Thomas · Principal Accounting Officer | Common Stock | S — Open market or private sale | −2,639 | 100.00 | SEC filing |
| 2026-05-26 | Tray Thomas · Principal Accounting Officer | Common Stock | S — Open market or private sale | −2,051 | 97.35 | SEC filing |
| 2026-05-19 | Clancy Paul J · Director | Common Stock | S — Open market or private sale | −15,000 | 94.93 | SEC filing |
| 2026-04-17 | CAGNONI PABLO J · President, Global Head of R&D | Common Stock | S — Open market or private sale | −18,667 | 96.50 | SEC filing |
| 2026-03-17 | CAGNONI PABLO J · President, R&D | Common Stock | S — Open market or private sale | −18,667 | 94.24 | SEC filing |
| 2026-02-19 | CAGNONI PABLO J · President, R&D | Common Stock | S — Open market or private sale | −18,668 | 100.91 | SEC filing |
| 2026-01-07 | Issa Mohamed Khairie · EVP, Head of US Oncology | Common Stock | S — Open market or private sale | −10,856 | 109.07 | SEC filing |
| 2026-01-05 | Stein Steven H · EVP & Chief Medical Officer | Common Stock | S — Open market or private sale | −15,634 | 101.70 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-08 | HARRIGAN EDMUND · Director | Non Qualfied Stock Option (right to buy) | A — Grant, award, or other acquisition | +6,111 | SEC filing |
| 2026-06-08 | High Katherine A · Director | Common Stock | A — Grant, award, or other acquisition | +1,642 | SEC filing |
| 2026-06-08 | BRAWLEY OTIS W · Director | Common Stock | A — Grant, award, or other acquisition | +1,642 | SEC filing |
| 2026-06-08 | High Katherine A · Director | Non Qualfied Stock Option (right to buy) | A — Grant, award, or other acquisition | +6,111 | SEC filing |
| 2026-06-08 | FOUSE JACQUALYN A · Director | Non Qualfied Stock Option (right to buy) | A — Grant, award, or other acquisition | +6,111 | SEC filing |
| 2026-06-08 | BIENAIME JEAN JACQUES · Director | Non Qualfied Stock Option (right to buy) | A — Grant, award, or other acquisition | +6,111 | SEC filing |
| 2026-06-08 | FOUSE JACQUALYN A · Director | Common Stock | A — Grant, award, or other acquisition | +1,642 | SEC filing |
| 2026-06-08 | Clancy Paul J · Director | Non Qualfied Stock Option (right to buy) | A — Grant, award, or other acquisition | +6,111 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.